Cargando…

Comparison of commercial dosimetric software platforms in patients treated with (177)Lu‐DOTATATE for peptide receptor radionuclide therapy

PURPOSE: The aim of this study was to quantitatively compare five commercial dosimetric software platforms based on the analysis of clinical datasets of patients who benefited from peptide receptor radionuclide therapy (PRRT) with (177)Lu‐DOTATATE (LUTATHERA(®)). METHODS: The dosimetric analysis was...

Descripción completa

Detalles Bibliográficos
Autores principales: Mora‐Ramirez, Erick, Santoro, Lore, Cassol, Emmanuelle, Ocampo‐Ramos, Juan C., Clayton, Naomi, Kayal, Gunjan, Chouaf, Soufiane, Trauchessec, Dorian, Pouget, Jean‐Pierre, Kotzki, Pierre‐Olivier, Deshayes, Emmanuel, Bardiès, Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589428/
https://www.ncbi.nlm.nih.gov/pubmed/32632928
http://dx.doi.org/10.1002/mp.14375
_version_ 1783600576838238208
author Mora‐Ramirez, Erick
Santoro, Lore
Cassol, Emmanuelle
Ocampo‐Ramos, Juan C.
Clayton, Naomi
Kayal, Gunjan
Chouaf, Soufiane
Trauchessec, Dorian
Pouget, Jean‐Pierre
Kotzki, Pierre‐Olivier
Deshayes, Emmanuel
Bardiès, Manuel
author_facet Mora‐Ramirez, Erick
Santoro, Lore
Cassol, Emmanuelle
Ocampo‐Ramos, Juan C.
Clayton, Naomi
Kayal, Gunjan
Chouaf, Soufiane
Trauchessec, Dorian
Pouget, Jean‐Pierre
Kotzki, Pierre‐Olivier
Deshayes, Emmanuel
Bardiès, Manuel
author_sort Mora‐Ramirez, Erick
collection PubMed
description PURPOSE: The aim of this study was to quantitatively compare five commercial dosimetric software platforms based on the analysis of clinical datasets of patients who benefited from peptide receptor radionuclide therapy (PRRT) with (177)Lu‐DOTATATE (LUTATHERA(®)). METHODS: The dosimetric analysis was performed on two patients during two cycles of PRRT with (177)Lu. Single photon emission computed tomography/computed tomography images were acquired at 4, 24, 72, and 192 h post injection. Reconstructed images were generated using Dosimetry Toolkit(®) (DTK) from Xeleris™ and HybridRecon‐Oncology version_1.3_Dicom (HROD) from HERMES. Reconstructed images using DTK were analyzed using the same software to calculate time‐integrated activity coefficients (TIAC), and mean absorbed doses were estimated using OLINDA/EXM V1.0 with mass correction. Reconstructed images from HROD were uploaded into PLANET® OncoDose from DOSIsoft, STRATOS from Phillips, Hybrid Dosimetry Module™ from HERMES, and SurePlan™ MRT from MIM. Organ masses, TIACs, and mean absorbed doses were calculated from each application using their recommendations. RESULTS: The majority of organ mass estimates varied by <9.5% between all platforms. The highest variability for TIAC results between platforms was seen for the kidneys (28.2%) for the two patients and the two treatment cycles. Relative standard deviations in mean absorbed doses were slightly higher compared with those observed for TIAC, but remained of the same order of magnitude between all platforms. CONCLUSIONS: When applying a similar processing approach, results obtained were of the same order of magnitude regardless of the platforms used. However, the comparison of the performances of currently available platforms is still difficult as they do not all address the same parts of the dosimetric analysis workflow. In addition, the way in which data are handled in each part of the chain from data acquisition to absorbed doses may be different, which complicates the comparison exercise. Therefore, the dissemination of commercial solutions for absorbed dose calculation calls for the development of tools and standards allowing for the comparison of the performances between dosimetric software platforms.
format Online
Article
Text
id pubmed-7589428
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-75894282020-10-30 Comparison of commercial dosimetric software platforms in patients treated with (177)Lu‐DOTATATE for peptide receptor radionuclide therapy Mora‐Ramirez, Erick Santoro, Lore Cassol, Emmanuelle Ocampo‐Ramos, Juan C. Clayton, Naomi Kayal, Gunjan Chouaf, Soufiane Trauchessec, Dorian Pouget, Jean‐Pierre Kotzki, Pierre‐Olivier Deshayes, Emmanuel Bardiès, Manuel Med Phys COMPUTATIONAL AND EXPERIMENTAL DOSIMETRY PURPOSE: The aim of this study was to quantitatively compare five commercial dosimetric software platforms based on the analysis of clinical datasets of patients who benefited from peptide receptor radionuclide therapy (PRRT) with (177)Lu‐DOTATATE (LUTATHERA(®)). METHODS: The dosimetric analysis was performed on two patients during two cycles of PRRT with (177)Lu. Single photon emission computed tomography/computed tomography images were acquired at 4, 24, 72, and 192 h post injection. Reconstructed images were generated using Dosimetry Toolkit(®) (DTK) from Xeleris™ and HybridRecon‐Oncology version_1.3_Dicom (HROD) from HERMES. Reconstructed images using DTK were analyzed using the same software to calculate time‐integrated activity coefficients (TIAC), and mean absorbed doses were estimated using OLINDA/EXM V1.0 with mass correction. Reconstructed images from HROD were uploaded into PLANET® OncoDose from DOSIsoft, STRATOS from Phillips, Hybrid Dosimetry Module™ from HERMES, and SurePlan™ MRT from MIM. Organ masses, TIACs, and mean absorbed doses were calculated from each application using their recommendations. RESULTS: The majority of organ mass estimates varied by <9.5% between all platforms. The highest variability for TIAC results between platforms was seen for the kidneys (28.2%) for the two patients and the two treatment cycles. Relative standard deviations in mean absorbed doses were slightly higher compared with those observed for TIAC, but remained of the same order of magnitude between all platforms. CONCLUSIONS: When applying a similar processing approach, results obtained were of the same order of magnitude regardless of the platforms used. However, the comparison of the performances of currently available platforms is still difficult as they do not all address the same parts of the dosimetric analysis workflow. In addition, the way in which data are handled in each part of the chain from data acquisition to absorbed doses may be different, which complicates the comparison exercise. Therefore, the dissemination of commercial solutions for absorbed dose calculation calls for the development of tools and standards allowing for the comparison of the performances between dosimetric software platforms. John Wiley and Sons Inc. 2020-07-31 2020-09 /pmc/articles/PMC7589428/ /pubmed/32632928 http://dx.doi.org/10.1002/mp.14375 Text en © 2020 The Authors. Medical Physics published by Wiley Periodicals LLC on behalf of American Association of Physicists in Medicine. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle COMPUTATIONAL AND EXPERIMENTAL DOSIMETRY
Mora‐Ramirez, Erick
Santoro, Lore
Cassol, Emmanuelle
Ocampo‐Ramos, Juan C.
Clayton, Naomi
Kayal, Gunjan
Chouaf, Soufiane
Trauchessec, Dorian
Pouget, Jean‐Pierre
Kotzki, Pierre‐Olivier
Deshayes, Emmanuel
Bardiès, Manuel
Comparison of commercial dosimetric software platforms in patients treated with (177)Lu‐DOTATATE for peptide receptor radionuclide therapy
title Comparison of commercial dosimetric software platforms in patients treated with (177)Lu‐DOTATATE for peptide receptor radionuclide therapy
title_full Comparison of commercial dosimetric software platforms in patients treated with (177)Lu‐DOTATATE for peptide receptor radionuclide therapy
title_fullStr Comparison of commercial dosimetric software platforms in patients treated with (177)Lu‐DOTATATE for peptide receptor radionuclide therapy
title_full_unstemmed Comparison of commercial dosimetric software platforms in patients treated with (177)Lu‐DOTATATE for peptide receptor radionuclide therapy
title_short Comparison of commercial dosimetric software platforms in patients treated with (177)Lu‐DOTATATE for peptide receptor radionuclide therapy
title_sort comparison of commercial dosimetric software platforms in patients treated with (177)lu‐dotatate for peptide receptor radionuclide therapy
topic COMPUTATIONAL AND EXPERIMENTAL DOSIMETRY
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589428/
https://www.ncbi.nlm.nih.gov/pubmed/32632928
http://dx.doi.org/10.1002/mp.14375
work_keys_str_mv AT moraramirezerick comparisonofcommercialdosimetricsoftwareplatformsinpatientstreatedwith177ludotatateforpeptidereceptorradionuclidetherapy
AT santorolore comparisonofcommercialdosimetricsoftwareplatformsinpatientstreatedwith177ludotatateforpeptidereceptorradionuclidetherapy
AT cassolemmanuelle comparisonofcommercialdosimetricsoftwareplatformsinpatientstreatedwith177ludotatateforpeptidereceptorradionuclidetherapy
AT ocamporamosjuanc comparisonofcommercialdosimetricsoftwareplatformsinpatientstreatedwith177ludotatateforpeptidereceptorradionuclidetherapy
AT claytonnaomi comparisonofcommercialdosimetricsoftwareplatformsinpatientstreatedwith177ludotatateforpeptidereceptorradionuclidetherapy
AT kayalgunjan comparisonofcommercialdosimetricsoftwareplatformsinpatientstreatedwith177ludotatateforpeptidereceptorradionuclidetherapy
AT chouafsoufiane comparisonofcommercialdosimetricsoftwareplatformsinpatientstreatedwith177ludotatateforpeptidereceptorradionuclidetherapy
AT trauchessecdorian comparisonofcommercialdosimetricsoftwareplatformsinpatientstreatedwith177ludotatateforpeptidereceptorradionuclidetherapy
AT pougetjeanpierre comparisonofcommercialdosimetricsoftwareplatformsinpatientstreatedwith177ludotatateforpeptidereceptorradionuclidetherapy
AT kotzkipierreolivier comparisonofcommercialdosimetricsoftwareplatformsinpatientstreatedwith177ludotatateforpeptidereceptorradionuclidetherapy
AT deshayesemmanuel comparisonofcommercialdosimetricsoftwareplatformsinpatientstreatedwith177ludotatateforpeptidereceptorradionuclidetherapy
AT bardiesmanuel comparisonofcommercialdosimetricsoftwareplatformsinpatientstreatedwith177ludotatateforpeptidereceptorradionuclidetherapy